Skip to main content

Panelists discuss how recent advances in Alzheimer’s disease, including amyloid-targeting therapies like lecanemab and donanemab, along with the growing role of blood-based biomarkers for early diagnosis and monitoring, are transforming treatment paradigms, enabling disease modification and personalized care while improving accessibility and reducing barriers to diagnosis.:

Source: Neurology Read More